TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02701231
Drug: Systemic anti-tumor therapy
Normalized name: human breast tumor cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic anti-tumor therapy includes targeted therapies, chemotherapy and best supportive care, according to NCCN non-small cell lung cancer(NSCLC) and small cell lung cancer(SCLC) guidelines. SCLC patients will receive six cycles of cisplatin and etoposide. NSCLC patients will receive EGFR and ALK test. With sensitive result the first-line therapy will be Erlotinib/Gefitinib/Crizotinib. If insensitive, the patient will receive six cycles of cisplatin and pemetrexed. Then the patient will receive tumor response evaluation. The patient with response or stable disease will receive maintenance therapy with one or some of the drugs including bevacizumab, pemetrexed, gemcitabine and docetaxel until disease progression. During experience all patients will receive clinical observation. Once proven for disease progression the patient will finish the experiment.
Study: NCT01359423
Drug: Percutaneous transluminal angioplasty of femoropopliteal artery lesions with primary long
Normalized name: scabies lesion lysate (human)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be randomized in a two-by-two factorial manner according to the use of IVUS guidance (IVUS guidance vs. no IVUS guidance) for the PCI and the duration of dual anti-platelet therapy (100 mg/day aspirin and 75mg/day clopidogrel for 6 months vs. 12 months) after PCI. Each randomization of the enrolled subjects will be done 1:1.
Study: NCT04356118
Drug: intrathcal methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intrathecal chemotherapy specified dose on specified days.
Study: NCT00692146
Drug: AZD1386
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral solution fixed dose (95 mg given orally on two occasions)
Study: NCT00692146
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral solution fixed dose (95 mg given orally on two occasions)
Study: NCT03629600
Drug: Rectal Form Indometacin
Normalized name: indomethacin Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-ERCP rectal administration of 100 MG Indomethacin
Study: NCT01452594
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT03863483
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% sodium chloride injection as placebo will be administered intravenously at a fixed dose of 100 milliliters (mL) on Day 1 of each 21-day cycle.
Study: NCT02316249
Drug: Estradiol
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will be instructed to digitally apply 0.5mg of cream inside vagina every night for 2 weeks. After 2 weeks they will switch to 2 nights weekly.
Study: NCT03235076
Drug: BAY1101042
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of 10 mg BAY 1101042 (given as 5 mg MR tablets)
Study: NCT00633386
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 400 mg oral capsule as a single dose 1 hour prior to surgery and 200 mg oral capsule as a single dose as needed post-surgery
Study: NCT01414075
Drug: Oral Iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered per oral dose and schedule specified in the arm.
Study: NCT01414075
Drug: IV Iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered per IV dose and schedule specified in the arm.
Study: NCT03151460
Drug: Dopamine Agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients were assessed in two experimental conditions that were performed on different days, with an intersession interval of about one month. In the off condition PD subjects performed the experimental tasks in the morning after 12/18 hours of Dopamine Agent withdrawal. In the on condition they were examined 90-120 minutes after they had taken their first morning dose of levodopa and/or dopamine agonists.
Study: NCT01300052
Drug: AN2728 ointment, 2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: AN2728 ointment, 2%, applied twice daily for 12 weeks
Study: NCT00887328
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo provided as 50mg lyophilised powder to be reconstituted with sterile water in glass vials indistinguishable from active drug
Study: NCT00741611
Drug: Anti-arrhythmic drugs
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 anti-arrhythmic drugs administered at the labeled dosage for atrial fibrillation
Study: NCT02859948
Drug: SKLB1028
Approvals — FDA: no, EMA: no, PMDA: no
Description: SKLB1028 capsules in six doses beginning at 20 mg and rising to 200 mg.
Study: NCT01859767
Drug: [123I]MNI-672 SPECT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be dosed by intravenous injection to a target dose of 5 mCi and not to exceed 5.5 (not \>10% of 5 mCi limit) I-123 MNI-672 prior to the SPECT scan.
Study: NCT01286324
Drug: Placebo Tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01124136
Drug: Standard of Care (Control)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of Care Therapy consists of medication management only to support heart for rhythm, anticoagulation, and rate, and comorbid symptoms, i.e. diuretics, lipid lowering.
Study: NCT00027859
Drug: therapeutic hydrocortisone
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03334448
Drug: LY900014-U200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT03334448
Drug: LY900014-U100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT00290251
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo given once daily for 3 menstrual cycles or 90 - 102 days
Study: NCT00586482
Drug: Placebo Lozenge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo lozenges, matching in appearance the 2 and 4 mg active nicotine lozenges, taken by mouth without restriction from 7 pm the night before surgery to the time of surgical admission the next day and a 2 minute behavioral intervention.
Study: NCT00886236
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 1200 mg (24 cc) by mouth 1 hour prior to surgery AND Placebo 300 mg (6cc) by mouth x 6 doses after surgery (0800PM the evening of surgery, 0800AM postoperative day 1, 0200PM postoperative day 1, 0800PM postoperative day 1, 0800AM postoperative day 2, 1200PM postoperative day 2)
Study: NCT00384176
Drug: Leucovorin (in FOLFOX)
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: intravenous infusion
Study: NCT04439773
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: the control group will be given the same volume of saline.
Study: NCT00379990
Drug: GW274150
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg /day
Study: NCT00379990
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 7.5 mg/day
Study: NCT03852459
Drug: S-Ibuprofen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Gel 5%
Study: NCT03852459
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle Gel
Study: NCT03380533
Drug: Placebo Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adhesive patch with the same macroscopic characteristics to the buprenorphine patch, without drugs.
Study: NCT03380533
Drug: Multimodal Oral Scheme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac 75mg c 12h Tramadol 50mg c 12h. Rescues with tramadol 50 mg (maximum rescue dose 150mg, minimum frequency between rescues 4hs)
Study: NCT01329731
Drug: elmex® gelée
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.25% fluoride (elmex® gelée) Dosage: Weekly brushing with 0.5g of respective gel Route: Intraoral topical
Study: NCT03380533
Drug: Placebo Tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet that the patient consumes every 8 hours during the first five days
Study: NCT00920088
Drug: Flurbiprofen
Normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flurbiprofen 50mg
Study: NCT00920088
Drug: GSK2248761
Approvals — FDA: no, EMA: no, PMDA: no
Description: NNRTI under investigation
Study: NCT03881345
Drug: Anticoagulants
Normalized name: ANTICOAGULANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: anticoagulation according to the main diagnosis
Study: NCT01922089
Drug: LCZ696
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCZ696 50 mg/100 mg/200 mg bid
Study: NCT02113176
Drug: Minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01072266
Drug: INCB028060
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg and 50 mg capsules will be provided and dosed per the dosing schedule.
Study: NCT01817465
Drug: Motilitone ®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01817465
Drug: Pantoline®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01817465
Drug: Motilitone® and Pantoline®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00430950
Drug: olmesartan medoxomil (OM)+ hydrochlorothiazide (HCTZ) tablets
Normalized name: hydrochlorothiazide / olmesartan medoxomil Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: olmesartan medoxomil (OM)+ hydrochlorothiazide (HCTZ)tablets 40mg/25mg + 20mg/25mg matching placebo tablets once daily for 8 weeks
Study: NCT00430950
Drug: olmesartan medoxomil (OM)/ hydrochlorothiazide (HCTZ) 20mg/25mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ)20mg/25mg tablet + 40mg/25mg matching placebo tablet once a day for 8 weeks
Study: NCT04225728
Drug: Iron Sucrose IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention will consisted of the administration for the IV route.~-The IV route in two doses will be diluted bolus injection of iron or normal saline at day 0 and day 14.
Study: NCT04225728
Drug: Ferric polymaltose hydroxide complex IM
Normalized name: ferric hydroxide
DrugBank: Ferric hydroxide (DB13423)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention will consisted of the administration for the IM route. Drug will be given in two series of injection; the first series will began at day 0 and consist of administration of 300 mg of iron per day in intramuscular injection up to the half of the total dose and the second series will began at day 14 for the administration of the other half with the same scheme than the first.
Study: NCT00005586
Drug: L-leucovorin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00005586
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00613834
Drug: Sterile Saline
Normalized name: Aqua Care Sterile Saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 ml intrauterine infusion of sterile saline using a sterile 3 mm Novak curette will be infused slowly over 4 1/2 minutes
Study: NCT00717184
Drug: Interleukin, NK cells
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02030314
Drug: Chlorthalidone
Normalized name: Chlorthalidone
DrugBank: Chlorthalidone (DB00310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: treatment of resistant hypertension in kidney transplant patients
Study: NCT00821366
Drug: ARV treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Households including ARV patients who receive the ARV treatment and associated support provided as part of government's ARV treatment programme
Study: NCT03096275
Drug: CYC
Normalized name: Cycrin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients were treated with Glucocorticoids and cyclophosphamide sequentially with azathioprine
Study: NCT03096275
Drug: Glucocorticoids
Normalized name: GLUCOCORTICOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in the experimental group and comparator group were treated with Glucocorticoids and then gradually tapered
Study: NCT03676751
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zithromax® for oral suspension is supplied in bottles containing azithromycin dehydrate powder equivalent to 1200mg per bottle and the following inactive ingredients: sucrose; tribasic anhydrous sodium phosphate; hydroxypropyl cellulose; xanthan gum; FD\&C Red #40; and flavoring including spray dried artificial cherry, crème de vanilla, and banana. After constitution, a 5mL suspension contains 200mg of azithromycin.
Study: NCT03676751
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral suspension of placebo for azithromycin
Study: NCT03173053
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tablet
Study: NCT03173053
Drug: Clindamycin
Normalized name: Clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tablet
Study: NCT03173053
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tablet
Study: NCT01690221
Drug: VEN 307
Normalized name: Apis mellifera ven protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: VEN307 applied three times a day, in and around the anus, for 28 days.
Study: NCT01690221
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cream applied three times a day, in and around the anus, for 28 days.
Study: NCT03801538
Drug: Nucleoside Analog (Substance)
Normalized name: Nucleoside analog (substance)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients do not need to change their NAs treatment.
Study: NCT04309253
Drug: PMPBB3
Approvals — FDA: no, EMA: no, PMDA: no
Description: F-18 PMPBB3 PET Imaging
Study: NCT04309253
Drug: AV45
Normalized name: TITANIUM DIOXIDE 2.8 g in 100 g / ZINC OXIDE 3.6 g in 100 g TOPICAL CREAM [AV453902 Avalon Organics Intense Defense Sheer Moisture SPF10]
Approvals — FDA: no, EMA: no, PMDA: no
Description: F-18 AV45 PET Imaging
Study: NCT00398931
Drug: Comparator : placebo (unspecified) /Duration of Treatment : 5 Years
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03330782
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Remifentanil was infused at predetermined effect-site concentration prior to propofol infusion (initial concentration: 3.0 ng/ml) in elderly patients (65-80 years)
Study: NCT03330782
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Remifentanil was infused at predetermined effect-site concentration prior to propofol infusion (initial concentration: 3.0 ng/ml) in adult patients (20-60 years)
Study: NCT03357055
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group will receive an intravenous (IV) infusion of 10 ml of normal saline in a 10 ml syringe over 10 minutes starting 10 minutes before pneumatic tourniquet inflation. Throughout the procedure, patients will receive 10ml/hour normal saline infusion until the end of operation
Study: NCT01400620
Drug: IZN-6N4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral rinse containing 1% botanical extracts, 15 cc rinse 3 times per day, for up to 9 weeks
Study: NCT03918590
Drug: nepafenac 0.3% suspension (Ilevro; Alcon, Fort Worth, TX)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NSAID
Study: NCT03918590
Drug: Theratears tear drop, (Akron, Ann 111 Arbor, MI)
Approvals — FDA: no, EMA: no, PMDA: no
Description: preservative-free Artificial Tears
Study: NCT00492765
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: dosage and frequency as per Biogen Idec protocol
Study: NCT00492765
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: dosage and frequency the same as simvastatin as per Biogen Idec Protocol
Study: NCT02326025
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered IV
Study: NCT02021370
Drug: BAY85-3934
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25mg Tablet
Study: NCT02021370
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tablet
Study: NCT00741936
Drug: MaZiRenWan (MZRW)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MZRW granule dissolved in 150ml hot water (oral), 7.5g/sachet, twice daily
Study: NCT03236740
Drug: Ethinyl Estradiol-cyprosterone acetate
Normalized name: cyproterone / ethinyl estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethinyl Estradiol-cyprosterone acetate in the form of OCPs will be taken cyclically by the participants.
Study: NCT00741936
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo granule dissolved in 150ml hot water (oral), 7.5g/sachet, twice daily
Study: NCT00109759
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00321737
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexlansoprazole placebo-matching capsules, orally, once daily for up to six months.
Study: NCT02025751
Drug: Placebo Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: One placebo spray dose 30 minutes before meals and before bed for 28 days (QID)
Study: NCT01870245
Drug: ACHN-975
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous multiple dose
Study: NCT01870245
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous multiple dose
Study: NCT03885882
Drug: E0302 SR1
Approvals — FDA: no, EMA: no, PMDA: no
Description: E0302 SR1, oral tablet.
Study: NCT03885882
Drug: E0302 SR3
Approvals — FDA: no, EMA: no, PMDA: no
Description: E0302 SR3, oral tablet.
Study: NCT03885882
Drug: E0302 SR2
Approvals — FDA: no, EMA: no, PMDA: no
Description: E0302 SR2, oral tablet.
Study: NCT03885882
Drug: E0302 IR
Approvals — FDA: no, EMA: no, PMDA: no
Description: E0302 IR, oral tablet.
Study: NCT03977974
Drug: LY3526318
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT03977974
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT04400760
Drug: DAPA Tx
Approvals — FDA: no, EMA: no, PMDA: no
Description: The intervention, dapagliflozin will be administered 10mg per oral daily for two weeks.
Study: NCT04300829
Drug: cicaderma + simple hygiene rules
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cicaderma ointment (2 applications / day: after the radiotherapy session) and in the evening) + simple hygiene rules
Study: NCT02624726
Drug: 5 Fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 Fluorouracil: 400mg/m2, bolus infusion in \<5min followed by 5 Fluorouracil: 2400mg/m2, i.v in 46 hours continuous infusion (cycle repeated every two weeks)
Study: NCT02624726
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Leucovorin: 400mg/m2, i.v in 2 hours infusion (cycle repeated every two weeks)
Study: NCT03431974
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microcrystalline filled capsule to mimic capsule containing aminopterin tablets
Study: NCT02499315
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablets in 20 count bottles. Dose strengths include 5, 25, and 50 mg tablets.
Study: NCT00003972
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00588640
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: After randomization, patients will take the study drug or placebo for 12 days and then they will cross-over to the opposite arm for another 12 days. The study will end on day 24.
Study: NCT00522444
Drug: Nebulized Magnesium Sulfate
Normalized name: Hydra-Neb
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6.3% solution of magnesium heptahydrate, which is equivalent to 3.18% anhydrous magnesium sulfate
Study: NCT03655236
Drug: K0706
Normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: low dose, orally, once-daily
Study: NCT03655236
Drug: K0706
Normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: high dose, orally, once-daily
Study: NCT04219735
Drug: Minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Minocycline 100mg BID
Study: NCT04219735
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT03516084
Drug: ZL-2306(nirapairb)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The initial dose is 300mg QD or 200mg QD based on baseline weight and platelet count.
Study: NCT03516084
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The initial dose is 300mg QD or 200mg QD based on baseline weight and platelet count.
Study: NCT01859741
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: administered IV
Study: NCT02551575
Drug: Treatment of MTX and HCQ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate: 10-15mg per week according to patient's weight, oral, for 24 weeks.~Hydroxychloroquine: 200mg, 2 times a day, oral, for 24 weeks. Qingre Huoxue granule placebo: 10g, 2 times a day, oral, for 24 weeks. Qingre Huoxue external preparation placebo: 20g, 1 times a day, external, for 4 weeks, then 10g, 1 times a day, external, for 8 weeks.
Study: NCT01454622
Drug: A (canagliflozin and metformin IR individual tablets) / B (canagliflozin/metformin IR FDC tablets)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment A: Canagliflozin: Type = 1, unit = mg, number = 100, form = tablet, route = oral use + metformin IR: Type = 2, unit = mg, number = 1000, form = tablet, route = oral use. One canagliflozin tablet and 2 metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period 1 followed 10-15 days later by Treatment B (canagliflozin/metformin IR FDC): Type = 2, unit = mg, number = 50/1000, form = tablet, route = oral use. Two canagliflozin/metformin IR FDC tablets taken orally on Day 1 of Treatment Period 2
Study: NCT02551575
Drug: Integrative Medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qingre Huoxue granule: 10g, 2 times a day, oral, for 24 weeks. Qingre Huoxue external preparation: 20g, 1 times a day, external, for 4 weeks, then 10g, 1 times a day, external, for 8 weeks.~Methotrexate: 10-15mg per week according to patient's weight, oral, for 24 weeks.~Hydroxychloroquine: 200mg, 3 times a day, oral, for 24 weeks.